Medicure Inc.
MPH
Rank in Stocks
#25161
Medicure Inc. is a biopharmaceutical firm focused on developing, researching,... Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Share Price
$2.68
Last synced: 2026-11-09
Market Cap
$27.94M
Change (1 day)
0.80%
Change (1 year)
190.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Medicure Inc. (MPH)
Category
Healthcare
Operating Margin for Medicure Inc. (MPH)
Operating Margin as of November 2026 TTM: -22.62%
According to Medicure Inc.'s latest financial reports, its current operating margin (TTM) is -22.62%. At the end of 2025 the company had an operating margin of -23.87%.
Operating Margin history for Medicure Inc. from 2001 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -22.62% | -5.24% |
| 2025 | -23.87% | 91.11% |
| 2024 | -12.49% | 217.01% |
| 2023 | -3.94% | -169.37% |
| 2022 | 5.68% | -315.15% |
| 2021 | -2.64% | -95.79% |
| 2020 | -62.76% | 18.01% |
| 2019 | -53.18% | 1,163.18% |
| 2018 | -4.21% | -131.28% |
| 2017 | 13.46% | -23.91% |
| 2016 | 17.69% | -17.26% |
| 2015 | 21.38% | 73.40% |
| 2014 | 12.33% | -115.38% |
| 2013 | -80.17% | -38,276.19% |
| 2012 | 0.21% | -100.61% |
| 2011 | -34.38% | -67.46% |
| 2010 | -105.66% | -27.57% |
| 2009 | -145.88% | -92.15% |
| 2008 | -1,857.66% | 254.91% |
| 2007 | -523.41% | -87.82% |
| 2006 | -4,298.81% | 28.02% |
| 2005 | -3,357.87% | 149.75% |
| 2004 | -1,344.47% | -22.65% |
| 2003 | -1,738.09% | -17.51% |
| 2002 | -2,107.03% | -11.42% |
| 2001 | -2,378.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.86% |
DE
|
|
| 19.68% | -100.87% |
DE
|
|
| 13.26% | -100.59% |
JP
|
|
| 17.08% | -100.76% |
CH
|
|
| 14.92% | -100.66% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Medicure Inc.'s operating margin
What is Medicure Inc.'s operating margin?
Medicure Inc.'s operating margin is -22.62%, as of Nov 2026.
What was Medicure Inc.'s operating margin in 2025?
In 2025, Medicure Inc.'s operating margin was -23.87%, compared with -12.49% in 2024.
How has Medicure Inc.'s operating margin changed since 2020?
From 2020 to 2025, Medicure Inc.'s operating margin was highest in 2022 (5.68%) and lowest in 2020 (-62.76%).
How does Medicure Inc.'s operating margin compare with similar companies?
Medicure Inc.'s operating margin (-22.62%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.